Main variables;No. of employees;Total
No. of companies carrying out R&D in Biotechnology;Fewer than 250 employees;975
No. of companies carrying out R&D in Biotechnology;250 or more employees;81
No. of companies carrying out R&D in Biotechnology;Total;1,056
%Companies according to biotechnology used: Genetic code;Fewer than 250 employees;35
%Companies according to biotechnology used: Genetic code;250 or more employees;46
%Companies according to biotechnology used: Genetic code;Total;36
%Companies according to biotechnology used: Functional units;Fewer than 250 employees;44
%Companies according to biotechnology used: Functional units;250 or more employees;50
%Companies according to biotechnology used: Functional units;Total;45
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Fewer than 250 employees;26
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;250 or more employees;45
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Total;27
%Companies according to biotechnology used: Bioprocesses;Fewer than 250 employees;45
%Companies according to biotechnology used: Bioprocesses;250 or more employees;66
%Companies according to biotechnology used: Bioprocesses;Total;47
%Companies according to biotechnology used: Sub-cellular organisms;Fewer than 250 employees;8
%Companies according to biotechnology used: Sub-cellular organisms;250 or more employees;15
%Companies according to biotechnology used: Sub-cellular organisms;Total;8
%Companies according to biotechnology used: Bio-computing;Fewer than 250 employees;24
%Companies according to biotechnology used: Bio-computing;250 or more employees;32
%Companies according to biotechnology used: Bio-computing;Total;25
%Companies according to biotechnology used: Nanobiotechnology;Fewer than 250 employees;13
%Companies according to biotechnology used: Nanobiotechnology;250 or more employees;16
%Companies according to biotechnology used: Nanobiotechnology;Total;13
%Companies according to biotechnology used: Other;Fewer than 250 employees;15
%Companies according to biotechnology used: Other;250 or more employees;13
%Companies according to biotechnology used: Other;Total;15
Companies in which biotechnology activities are: Main and/or exclusive;Fewer than 250 employees;538
Companies in which biotechnology activities are: Main and/or exclusive;250 or more employees;12
Companies in which biotechnology activities are: Main and/or exclusive;Total;551
Companies in which biotechnology activities are: A secondary line of business;Fewer than 250 employees;164
Companies in which biotechnology activities are: A secondary line of business;250 or more employees;19
Companies in which biotechnology activities are: A secondary line of business;Total;183
Companies in which biotechnology activities are: A tool necessary for production;Fewer than 250 employees;273
Companies in which biotechnology activities are: A tool necessary for production;250 or more employees;50
Companies in which biotechnology activities are: A tool necessary for production;Total;323
%Company by field(s) of ultimate application of biotechnology use: Human Health;Fewer than 250 employees;49
%Company by field(s) of ultimate application of biotechnology use: Human Health;250 or more employees;52
%Company by field(s) of ultimate application of biotechnology use: Human Health;Total;49
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Fewer than 250 employees;22
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;250 or more employees;3
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Total;20
%Company by field(s) of ultimate application of biotechnology use: Food products;Fewer than 250 employees;30
%Company by field(s) of ultimate application of biotechnology use: Food products;250 or more employees;36
%Company by field(s) of ultimate application of biotechnology use: Food products;Total;30
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Fewer than 250 employees;23
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;250 or more employees;13
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Total;23
%Company by field(s) of ultimate application of biotechnology use: Environment;Fewer than 250 employees;13
%Company by field(s) of ultimate application of biotechnology use: Environment;250 or more employees;17
%Company by field(s) of ultimate application of biotechnology use: Environment;Total;13
%Company by field(s) of ultimate application of biotechnology use: Industry;Fewer than 250 employees;13
%Company by field(s) of ultimate application of biotechnology use: Industry;250 or more employees;7
%Company by field(s) of ultimate application of biotechnology use: Industry;Total;12
Personnel in R&D in biotechnology (no. of persons);Fewer than 250 employees;7,908
Personnel in R&D in biotechnology (no. of persons);250 or more employees;2,811
Personnel in R&D in biotechnology (no. of persons);Total;10,719
Personnel in R&D in biotechnology (no. of persons): Researchers;Fewer than 250 employees;4,660
Personnel in R&D in biotechnology (no. of persons): Researchers;250 or more employees;1,470
Personnel in R&D in biotechnology (no. of persons): Researchers;Total;6,131
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;Fewer than 250 employees;3,247
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;250 or more employees;1,341
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;Total;4,588
Personnel in R&D in biotechnology (no. of persons): women;Fewer than 250 employees;4,291
Personnel in R&D in biotechnology (no. of persons): women;250 or more employees;1,749
Personnel in R&D in biotechnology (no. of persons): women;Total;6,040
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;Fewer than 250 employees;2,520
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;250 or more employees;891
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;Total;3,411
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;Fewer than 250 employees;1,772
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;250 or more employees;857
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;Total;2,629
Personnel in R&D in biotechnology (FTE);Fewer than 250 employees;5,651.3
Personnel in R&D in biotechnology (FTE);250 or more employees;2,099.5
Personnel in R&D in biotechnology (FTE);Total;7,750.8
Personnel in R&D in biotechnology (FTE): Researchers;Fewer than 250 employees;3,461.8
Personnel in R&D in biotechnology (FTE): Researchers;250 or more employees;1,056.3
Personnel in R&D in biotechnology (FTE): Researchers;Total;4,518.1
Personnel in R&D in biotechnology (FTE): Technicians and assistants;Fewer than 250 employees;2,189.4
Personnel in R&D in biotechnology (FTE): Technicians and assistants;250 or more employees;1,043.3
Personnel in R&D in biotechnology (FTE): Technicians and assistants;Total;3,232.7
Personnel in R&D in biotechnology (FTE): women;Fewer than 250 employees;3,133.9
Personnel in R&D in biotechnology (FTE): women;250 or more employees;1,337.5
Personnel in R&D in biotechnology (FTE): women;Total;4,471.4
Personnel in R&D in biotechnology (FTE): (women) Researchers;Fewer than 250 employees;1,912.0
Personnel in R&D in biotechnology (FTE): (women) Researchers;250 or more employees;650.7
Personnel in R&D in biotechnology (FTE): (women) Researchers;Total;2,562.7
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;Fewer than 250 employees;1,221.9
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;250 or more employees;686.8
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;Total;1,908.7
Internal expenditure on R&D (thousands of euros);Fewer than 250 employees;511,004
Internal expenditure on R&D (thousands of euros);250 or more employees;168,555
Internal expenditure on R&D (thousands of euros);Total;679,558
1) By nature of the expense: Current expenses;Fewer than 250 employees;470,651
1) By nature of the expense: Current expenses;250 or more employees;163,981
1) By nature of the expense: Current expenses;Total;634,631
1.1) Remuneration to researchers;Fewer than 250 employees;167,208
1.1) Remuneration to researchers;250 or more employees;61,649
1.1) Remuneration to researchers;Total;228,857
1.2) Remuneration to technicians and assistants;Fewer than 250 employees;63,658
1.2) Remuneration to technicians and assistants;250 or more employees;40,840
1.2) Remuneration to technicians and assistants;Total;104,498
1.3) Other current expenses;Fewer than 250 employees;239,785
1.3) Other current expenses;250 or more employees;61,492
1.3) Other current expenses;Total;301,276
2) By nature of the expense: Capital expenses;Fewer than 250 employees;40,353
2) By nature of the expense: Capital expenses;250 or more employees;4,574
2) By nature of the expense: Capital expenses;Total;44,927
2.1) Land and buildings;Fewer than 250 employees;2,519
2.1) Land and buildings;250 or more employees;66
2.1) Land and buildings;Total;2,585
2.2) Equipment and instruments;Fewer than 250 employees;19,828
2.2) Equipment and instruments;250 or more employees;3,741
2.2) Equipment and instruments;Total;23,569
2.3) Acquisition of specific R&D software;Fewer than 250 employees;780
2.3) Acquisition of specific R&D software;250 or more employees;612
2.3) Acquisition of specific R&D software;Total;1,392
2.4) Otros productos de propiedad intelectual específicos para I+D;Fewer than 250 employees;17,226
2.4) Otros productos de propiedad intelectual específicos para I+D;250 or more employees;155
2.4) Otros productos de propiedad intelectual específicos para I+D;Total;17,381
1) By origin of the funds: National funds;Fewer than 250 employees;417,983
1) By origin of the funds: National funds;250 or more employees;138,313
1) By origin of the funds: National funds;Total;556,297
1.1) Own funds;Fewer than 250 employees;301,946
1.1) Own funds;250 or more employees;85,064
1.1) Own funds;Total;387,010
1.2) From companies;Fewer than 250 employees;49,801
1.2) From companies;250 or more employees;36,223
1.2) From companies;Total;86,025
1.3) Public Administration funds;Fewer than 250 employees;61,218
1.3) Public Administration funds;250 or more employees;13,546
1.3) Public Administration funds;Total;74,764
1.4) From Universities;Fewer than 250 employees;408
1.4) From Universities;250 or more employees;0
1.4) From Universities;Total;408
1.5) From non profit private institutions;Fewer than 250 employees;4,610
1.5) From non profit private institutions;250 or more employees;3,480
1.5) From non profit private institutions;Total;8,090
1) By origin of the funds: Foreign funds;Fewer than 250 employees;93,020
1) By origin of the funds: Foreign funds;250 or more employees;30,241
1) By origin of the funds: Foreign funds;Total;123,262
2.1) From EU programmes;Fewer than 250 employees;18,993
2.1) From EU programmes;250 or more employees;6,132
2.1) From EU programmes;Total;25,125
2.2) Other foreign funds;Fewer than 250 employees;74,027
2.2) Other foreign funds;250 or more employees;24,109
2.2) Other foreign funds;Total;98,137
Purchase of R&D services in biotechnology (thousands of euros);Fewer than 250 employees;86,267
Purchase of R&D services in biotechnology (thousands of euros);250 or more employees;61,292
Purchase of R&D services in biotechnology (thousands of euros);Total;147,558
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Fewer than 250 employees;26,503
Purchase of R&D services in biotechnology (thousands of euros): In Spain;250 or more employees;50,373
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Total;76,875
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Fewer than 250 employees;59,764
Purchase of R&D services in biotechnology (thousands of euros): Abroad;250 or more employees;10,919
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Total;70,683
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Fewer than 250 employees;50
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;250 or more employees;25
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Total;49
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Fewer than 250 employees;14
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;250 or more employees;11
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Total;14
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Fewer than 250 employees;16
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;250 or more employees;15
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Total;16
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Fewer than 250 employees;13
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;250 or more employees;15
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Total;13
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Fewer than 250 employees;18
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;250 or more employees;13
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Total;18
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Fewer than 250 employees;19
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;250 or more employees;8
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Total;18
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Fewer than 250 employees;17
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;250 or more employees;14
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Total;17
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Fewer than 250 employees;38
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;250 or more employees;30
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Total;37
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Fewer than 250 employees;52
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;250 or more employees;40
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Total;51
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Fewer than 250 employees;18
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;250 or more employees;14
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Total;18
% Companies that have requested biotechnology patents in Biotechnology;Fewer than 250 employees;15
% Companies that have requested biotechnology patents in Biotechnology;250 or more employees;16
% Companies that have requested biotechnology patents in Biotechnology;Total;16
Number of patents requested;Fewer than 250 employees;602
Number of patents requested;250 or more employees;144
Number of patents requested;Total;746
% Companies with income of an international origin related to biotechnological activities;Fewer than 250 employees;23.9
% Companies with income of an international origin related to biotechnological activities;250 or more employees;16.0
% Companies with income of an international origin related to biotechnological activities;Total;23.3
% Turnover representing income of an international origin related to biotechnological activities;Fewer than 250 employees;5.70
% Turnover representing income of an international origin related to biotechnological activities;250 or more employees;0.70
% Turnover representing income of an international origin related to biotechnological activities;Total;1.20
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Fewer than 250 employees;49.30
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;250 or more employees;69.70
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Total;60.40
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Fewer than 250 employees;50.70
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;250 or more employees;30.30
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Total;39.60
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Fewer than 250 employees;92.60
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;250 or more employees;71.20
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Total;80.90
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Fewer than 250 employees;5.50
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;250 or more employees;27.90
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total;17.80
% Income of an international origin related with activities according to the classification: Operating source abroad;Fewer than 250 employees;1.90
% Income of an international origin related with activities according to the classification: Operating source abroad;250 or more employees;0.80
% Income of an international origin related with activities according to the classification: Operating source abroad;Total;1.30
% Income of an international origin related with activities according to the classification: Other;Fewer than 250 employees;0.10
% Income of an international origin related with activities according to the classification: Other;250 or more employees;.
% Income of an international origin related with activities according to the classification: Other;Total;0.10